Overview of current advances in and future approaches to CLL management with BTK and Bcl-2 inhibitors, with patient cases illustrating criteria for treatment selection and sequencing and reference to new guidelines.

Poster presented at ASCO 2022 describing a HER2-targeted bispecific antibody in combination with chemotherapy, as first-line therapeutic options for patients with advanced HER2-positive gastric/gastroesophageal junction adenocarcinoma (GC/GEJC).

Poster presented at ASCO 2022 describing a HER2-targeted bispecific antibody in combination with chemotherapy, as first-line therapeutic options for patients with advanced HER2-positive breast cancer.

Investigating the potential of PD-1 inhibition in hepatocellular carcinoma (HCC) patients who have previously been treated with a kinase inhibitor.

Exploring the combination of PD-1 inhibition and chemotherapy as an emerging therapeutic option for recurrent or metastatic nasopharyngeal carcinoma (RM NPC).